Second approvable letter for GSK and Pozen migraine treatment

Share this article:

The FDA delivered a further setback to GlaxoSmithKline and Pozen's developmental migraine treatment Trexima yesterday in the form of a second approvable letter seeking more data related to the drug.

Both companies said the FDA asked Pozen to address potential implications from a preclinical study into chromosomal risks in which genotoxicity was seen for the combination of naproxen sodium and sumatriptan, but not with either component alone.

Trexima combines GSK's migraine drug Imitrex (sumatriptan) with the generic anti-inflammatory, naproxen sodium.

The companies said they plan to request a meeting with the FDA as quickly as possible to discuss necessary steps to address the agency's concerns.

In June 2006, the FDA also issued an approvable letter on Trexima that asked for additional drug safety information. The FDA did not accept the drugmakers' additional data submitted by the company in November. The companies then filed additional safety data in January.

Imitrex currently holds around 56% of the migraine drug market and brought in $1.1 billion in sales for GlaxoSmithKline in 2005. With Trexima, GSK and Pozen hope to replace Imitrex as the top migraine treatment when the drug's patent expires in 2009.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...